The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

CNBC's Kristina Partsinevelos joins 'Closing Bell' to discuss the stocks she's watching.

Moderna Chairman Noubar Afeyan says the trial results remind him of when his company developed its Covid-19 vaccine.

Moderna shares soared 172% after strong results for its vaccine for melanoma skin cancer. Elsewhere, the Evergrande saga came ...

CHICAGO, Aug 19 (Reuters) - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay ...

Moderna and Merck announced that a personalized mRNA melanoma vaccine met key goals in a Phase 3 trial. It could become ...

The company says a trial met its goal to prevent melanoma recurrence.

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.